No Data
ASCLETIS-B (01672.HK) spent 0.9685 million Hong Kong dollars to repurchase 0.15 million shares on April 3.
Gelonghui reported on April 3 that ASCLETIS-B (01672.HK) announced that on April 3, it spent 0.9685 million HKD to repurchase 0.15 million shares.
Ascletis Pharma Reports Positive Interim Results for Obesity Treatment; Shares Up 6%
Hong Kong stocks movement | ASCLETIS-B (01672) rose over 8% in early trading, with positive interim results reported from the Phase Ib trial of the obesity drug ASC30 in the USA.
ASCLETIS-B (01672) rose over 8% in early trading, as of this writing, it is up 4.58%, quoted at HKD 8.45, with a trading volume of HKD 16.3974 million.
Express News | Ascletis Pharma Inc - Asc30 Sq Injection Shows 36-Day Half-Life in Obesity Patients
Express News | Ascletis Pharma: Announces Positive Interim Results From Its U.S. Phase Ib Trial With Asc30
ASCLETIS-B (01672): Expected to become the first-in-class subcutaneous small molecule GLP-1R agonist ASC30 in the USA, with positive mid-term results from the Phase Ib trial.
ASCLETIS-B (01672) announced that it is conducting a randomized, double-blind, placebo-controlled trial of ASC3 in the USA...
Anivid : over priced...